{"pmid":32328364,"pmcid":"PMC7170017","title":"Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy.","text":["Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy.","Coronavirus disease 2019 (COVID-19) is a pandemic. Neurological complications of COVID-19 have not been reported. Encephalopathy has not been described as a presenting symptom or complication of COVID-19. We report a case of a 74-year-old patient who traveled from Europe to the United States and presented with encephalopathy and COVID-19.","Cureus","Filatov, Asia","Sharma, Pamraj","Hindi, Fawzi","Espinosa, Patricio S","32328364"],"abstract":["Coronavirus disease 2019 (COVID-19) is a pandemic. Neurological complications of COVID-19 have not been reported. Encephalopathy has not been described as a presenting symptom or complication of COVID-19. We report a case of a 74-year-old patient who traveled from Europe to the United States and presented with encephalopathy and COVID-19."],"journal":"Cureus","authors":["Filatov, Asia","Sharma, Pamraj","Hindi, Fawzi","Espinosa, Patricio S"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32328364","week":"202017|Apr 20 - Apr 26","doi":"10.7759/cureus.7352","keywords":["covid-19","encephalopathy"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664996914754486272,"score":8.518259,"similar":[{"pmid":32329044,"title":"Neurological complications of coronavirus and COVID-19.","text":["Neurological complications of coronavirus and COVID-19.","INTRODUCTION: Clinical and experimental studies have shown that the coronavirus family has a certain tropism for the central nervous system. Seven types of coronavirus can infect humans. DEVELOPMENT: Coronaviruses are not always confined to the respiratory tract, and under certain conditions they can invade the central nervous system and cause neurological pathologies. The potential for neuroinvasion is well documented in most human coronaviruses (OC-43, 229E, MERS and SARS) and in some animal coronaviruses (porcine haemagglutinating encephalomyelitis coronavirus). Neurological symptoms have been reported in patients affected by COVID-19, such as headache, dizziness, myalgia and anosmia, as well as cases of encephalopathy, encephalitis, necrotising haemorrhagic encephalopathy, stroke, epileptic seizures, rhabdomyolysis and Guillain-Barre syndrome, associated with SARS-CoV-2 infection. CONCLUSIONS: Future epidemiological studies and case records should elucidate the real incidence of these neurological complications, their pathogenic mechanisms and their therapeutic options.","Rev Neurol","Carod-Artal, F J","32329044"],"abstract":["INTRODUCTION: Clinical and experimental studies have shown that the coronavirus family has a certain tropism for the central nervous system. Seven types of coronavirus can infect humans. DEVELOPMENT: Coronaviruses are not always confined to the respiratory tract, and under certain conditions they can invade the central nervous system and cause neurological pathologies. The potential for neuroinvasion is well documented in most human coronaviruses (OC-43, 229E, MERS and SARS) and in some animal coronaviruses (porcine haemagglutinating encephalomyelitis coronavirus). Neurological symptoms have been reported in patients affected by COVID-19, such as headache, dizziness, myalgia and anosmia, as well as cases of encephalopathy, encephalitis, necrotising haemorrhagic encephalopathy, stroke, epileptic seizures, rhabdomyolysis and Guillain-Barre syndrome, associated with SARS-CoV-2 infection. CONCLUSIONS: Future epidemiological studies and case records should elucidate the real incidence of these neurological complications, their pathogenic mechanisms and their therapeutic options."],"journal":"Rev Neurol","authors":["Carod-Artal, F J"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329044","week":"202017|Apr 20 - Apr 26","doi":"10.33588/rn.7009.2020179","source":"PubMed","topics":["Diagnosis","Treatment","Mechanism"],"weight":1,"_version_":1664996914820546560,"score":256.63425},{"pmid":32320211,"title":"Neurological Insights of COVID-19 Pandemic.","text":["Neurological Insights of COVID-19 Pandemic.","The novel coronavirus SARS-CoV-2, which was identified after a recent outbreak in Wuhan, China, in December 2019, has kept the whole world in tenterhooks due to its severe life-threatening nature of the infection. The virus is unlike its previous counterparts, SARS-CoV and MERS-CoV, or anything the world has encountered before both in terms of virulence and severity of the infection. If scientific reports relevant to the SARS-CoV-2 virus are noted, it can be seen that the virus owes much of its killer properties to its unique structure that has a stronger binding affinity with the human angiotensin-converting enzyme 2 (hACE2) protein, which the viruses utilize as an entry point to gain accesses to its hosts. Recent reports suggest that it is not just the lung that the virus may be targeting; the human brain may soon emerge as the new abode of the virus. Already instances of patients with COVID-19 have been reported with mild (anosmia and ageusia) to severe (encephalopathy) neurological manifestations, and if that is so, then it gives us more reasons to be frightened of this killer virus. Keeping in mind that the situation does not worsen from here, immediate awareness and more thorough research regarding the neuroinvasive nature of the virus is the immediate need of the hour. Scientists globally also need to up their game to design more specific therapeutic strategies with the available information to counteract the pandemic. In this Viewpoint, we provide a brief outline of the currently known neurological manifestations of COVID-19 and discuss some probable ways to design therapeutic strategies to overcome the present global crisis.","ACS Chem Neurosci","Das, Gaurav","Mukherjee, Nabanita","Ghosh, Surajit","32320211"],"abstract":["The novel coronavirus SARS-CoV-2, which was identified after a recent outbreak in Wuhan, China, in December 2019, has kept the whole world in tenterhooks due to its severe life-threatening nature of the infection. The virus is unlike its previous counterparts, SARS-CoV and MERS-CoV, or anything the world has encountered before both in terms of virulence and severity of the infection. If scientific reports relevant to the SARS-CoV-2 virus are noted, it can be seen that the virus owes much of its killer properties to its unique structure that has a stronger binding affinity with the human angiotensin-converting enzyme 2 (hACE2) protein, which the viruses utilize as an entry point to gain accesses to its hosts. Recent reports suggest that it is not just the lung that the virus may be targeting; the human brain may soon emerge as the new abode of the virus. Already instances of patients with COVID-19 have been reported with mild (anosmia and ageusia) to severe (encephalopathy) neurological manifestations, and if that is so, then it gives us more reasons to be frightened of this killer virus. Keeping in mind that the situation does not worsen from here, immediate awareness and more thorough research regarding the neuroinvasive nature of the virus is the immediate need of the hour. Scientists globally also need to up their game to design more specific therapeutic strategies with the available information to counteract the pandemic. In this Viewpoint, we provide a brief outline of the currently known neurological manifestations of COVID-19 and discuss some probable ways to design therapeutic strategies to overcome the present global crisis."],"journal":"ACS Chem Neurosci","authors":["Das, Gaurav","Mukherjee, Nabanita","Ghosh, Surajit"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320211","week":"202017|Apr 20 - Apr 26","doi":"10.1021/acschemneuro.0c00201","keywords":["covid-19","sars-cov-2","encephalopathy","hace2","neuroinvasive property","therapeutic intervention"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664815087667380225,"score":227.72185},{"pmid":32307298,"title":"Severe cerebral involvement in adult-onset hemophagocytic lymphohistiocytosis.","text":["Severe cerebral involvement in adult-onset hemophagocytic lymphohistiocytosis.","The diagnosis of hemophagocytic lymphohistiocytosis (HLH) with cerebral involvement is challenging given the rarity of HLH and its resemblance to the much more common severe sepsis. Timely diagnosis and treatment may be lifesaving. We report two cases demonstrating different and rare forms of severe brain involvement in adult patients with HLH: acute necrotizing encephalopathy, and diffuse hemorrhagic disease due to disseminated intravascular coagulation. Severe HLH with brain involvement in adults is rare. HLH with cerebral involvement should be considered in patients presenting with severe systemic inflammatory response syndrome (SIRS) but negative cultures and unusual or unexpectedly severe clinical and/or radiologic signs of cerebral dysfunction. Similar brain injury may occur in patients with cytokine storm syndrome due to COVID-19. BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) presents with fevers, rash, organomegaly, cytopenia, and increased triglycerides and ferritin (Ramos-Casals et al., 2014) [1]. Neurologic abnormalities are reported in about one-third of patients (Cai et al., 2017), including a few cases of acute necrotizing encephalopathy (ANE) (Xiujuan et al., 2015). Coagulation abnormalities are frequent in HLH patients (Valade et al., 2015). OBJECTIVE: To raise awareness about the importance of early diagnosis and treatment of HLH with neurological involvement to prevent serious complications and demise.","J Clin Neurosci","Radmanesh, Farid","Rodriguez-Pla, Alicia","Pincus, Michael D","Burns, Joseph D","32307298"],"abstract":["The diagnosis of hemophagocytic lymphohistiocytosis (HLH) with cerebral involvement is challenging given the rarity of HLH and its resemblance to the much more common severe sepsis. Timely diagnosis and treatment may be lifesaving. We report two cases demonstrating different and rare forms of severe brain involvement in adult patients with HLH: acute necrotizing encephalopathy, and diffuse hemorrhagic disease due to disseminated intravascular coagulation. Severe HLH with brain involvement in adults is rare. HLH with cerebral involvement should be considered in patients presenting with severe systemic inflammatory response syndrome (SIRS) but negative cultures and unusual or unexpectedly severe clinical and/or radiologic signs of cerebral dysfunction. Similar brain injury may occur in patients with cytokine storm syndrome due to COVID-19. BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) presents with fevers, rash, organomegaly, cytopenia, and increased triglycerides and ferritin (Ramos-Casals et al., 2014) [1]. Neurologic abnormalities are reported in about one-third of patients (Cai et al., 2017), including a few cases of acute necrotizing encephalopathy (ANE) (Xiujuan et al., 2015). Coagulation abnormalities are frequent in HLH patients (Valade et al., 2015). OBJECTIVE: To raise awareness about the importance of early diagnosis and treatment of HLH with neurological involvement to prevent serious complications and demise."],"journal":"J Clin Neurosci","authors":["Radmanesh, Farid","Rodriguez-Pla, Alicia","Pincus, Michael D","Burns, Joseph D"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32307298","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jocn.2020.04.054","keywords":["acute necrotizing encephalopathy","adult onset still's disease","diffuse hemorrhagic encephalopathy","disseminated intravascular coagulation","hemophagocytic syndrome"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["organomegaly","cytopenia"],"e_drugs":["Triglycerides"],"_version_":1664632501560147968,"score":199.86829},{"pmid":32293714,"title":"Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019.","text":["Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019.","There has been a global outbreak of coronavirus disease 2019 (COVID-19) since December 2019. In clinical practice, not only fever and respiratory tract symptoms but also multiple organ symptoms are observed in patients diagnosed with COVID-19. Herein, we report a rare case of a patient diagnosed with COVID-19 who manifested with concomitant neurological symptoms. The patient developed fever and respiratory symptoms at disease onset, followed by muscle soreness, and subsequently altered consciousness and psychiatric symptoms, with positive signs based on neurological examination. The patient tested positive for the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) nucleic acid (throat swab). Further, chest computed tomography (CT) revealed typical COVID-19 findings, and head CT did not reveal significant abnormalities. The patient recovered after treatment and was discharged. This rare case indicates that SARS-CoV-2 can invade the central nervous system, thus causing neurological symptoms and signs. This article is protected by copyright. All rights reserved.","J Med Virol","Yin, Rong","Feng, Wei","Wang, Tonghui","Chen, Gang","Wu, Tao","Chen, Dongrui","Lv, Tangfeng","Xiang, Dawei","32293714"],"abstract":["There has been a global outbreak of coronavirus disease 2019 (COVID-19) since December 2019. In clinical practice, not only fever and respiratory tract symptoms but also multiple organ symptoms are observed in patients diagnosed with COVID-19. Herein, we report a rare case of a patient diagnosed with COVID-19 who manifested with concomitant neurological symptoms. The patient developed fever and respiratory symptoms at disease onset, followed by muscle soreness, and subsequently altered consciousness and psychiatric symptoms, with positive signs based on neurological examination. The patient tested positive for the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) nucleic acid (throat swab). Further, chest computed tomography (CT) revealed typical COVID-19 findings, and head CT did not reveal significant abnormalities. The patient recovered after treatment and was discharged. This rare case indicates that SARS-CoV-2 can invade the central nervous system, thus causing neurological symptoms and signs. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Yin, Rong","Feng, Wei","Wang, Tonghui","Chen, Gang","Wu, Tao","Chen, Dongrui","Lv, Tangfeng","Xiang, Dawei"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293714","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25888","keywords":["covid-19","meningitis","neurological symptoms"],"source":"PubMed","topics":["NONE","Case Report"],"weight":1,"_version_":1664636192529842176,"score":130.4884},{"pmid":32314010,"title":"Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","text":["Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.","Rheumatol Int","Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho","32314010"],"abstract":["In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications."],"journal":"Rheumatol Int","authors":["Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314010","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s00296-020-04584-7","keywords":["covid-19","coronavirus","disease-modifying antirheumatic drugs","pneumonia","rheumatoid arthritis"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Wuhan","China","myalgia"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["lopinavir-ritonavir drug combination","Hydroxychloroquine"],"_version_":1664714520041357312,"score":129.03589}]}